Forgot your password?

Forgot your username?


NanoViricides’ drug FluCide found safe in small animal studies

Posted on 24 Oct 2013
Early results for the new flu drug FluCide® found to be safe in a non-GLP small animal safety/ toxicology study. These preliminary results support the company’s earlier reports of the FluCide® drug being effective in animal models of different influenza A virus strains. NanoViricides

Soft Tissue Regeneration’s First Bioengineered Matrix Successfully Implanted in 7 Patients

Posted on 24 Oct 2013
STR has started a clinical trial in Europe for its ACL device and has successfully implanted the device in 7 patients as of October 2013. Their device utilizes a synthetic scaffold that regenerates the entire ligament tissue resulting in better chances of full recovery.

Profound Medical’s Device on Fast Track for Commercialization

Posted on 23 Oct 2013
Profound’s unique device for Prostate cancer treatment is currently in Phase I clinical trials in Europe and Canada. Profound has also received FDA approval to conduct clinical trials in U.S that will begin soon in 2013. The company is on fast track to begin commercialization in Europ

7th Annual OneMedForum to address ‘train wreck’ called US healthcare

Posted on 23 Oct 2013
NEW YORK, Oct. 15, 2013 – OneMedForum announced today that a major theme of its 7th annual healthcare investing conference will be to provide investors with an outlook about how the healthcare system will function post-Obamacare. Moreover, it will also address the new financing opport

Orexigen: Anti-Obesity Drug Attempting to Enter Multiple Markets

Posted on 04 Oct 2013
Orexigen Therapeutics is a biopharmaceutical company that focuses its attention on the treatment of one of the most common diseases in existence today, obesity.

OneMedPlace announces program for the Seventh Annual OneMedForum: Investing in Healthcare 2014, Jan. 13-15

Posted on 04 Oct 2013
OneMedPlace announces program for the Seventh Annual OneMedForum: Investing in Healthcare 2014, Jan. 13-15

“InVivo Interim” InVivo (NVIV) President, CEO and CFO Frank Reynolds Resigns; Michael J. Astrue In As Interim CEO and Sean Moran in As Acting CFO

Posted on 29 Aug 2013
“InVivo Interim” InVivo (NVIV) President, CEO and CFO Frank Reynolds Resigns; Michael J. Astrue In As Interim CEO and Sean Moran in As Acting CFO Following our coverage of InVivo (NVIV) delaying the listing of its publicly traded stock in “Corporate Governance Gap”, published earlier

“Corporate Governance Gap” InVivo (NVIV) Delays Listing to National Securities Exchange “Postponed”; Amarantus BioScience (AMBS) DTC Chill Lifted. What is the Next Step for Corporate Governance in the Biotechnology Sector?

Posted on 06 Aug 2013
Recent challenges to biotechnology companies have been in the form of corporate governance issues, especially those undergoing rapid growth.  Two companies in particular, InVivo (NVIV) and Amarantus Bioscience (AMBS) both stand out for their recent, respective corporate governance iss

“SEC’s A Crowd” SEC Finally Issues Determination on Internet-Based Crowdfunding Platforms. How Will This Affect Fundraising?

Posted on 02 Aug 2013
One of the major obstacles of growth for Internet based Crowdfunding platforms in the U.S. has been the reaction of regulatory authorities. However, two “no-action letters”, dated March 26, 2013, were sent by the SEC to online equity-based crowdfunding portals FundersClub and AngelLis